Identification and Functional Characterization of IDS Gene Mutations Underlying Taiwanese Hunter Syndrome (Mucopolysaccharidosis Type II).
Hsiang-Yu LinRu-Yi TuSchu-Rern ChernYun-Ting LoSisca FranFang-Jie WeiSung-Fa HuangShin-Yu TsaiYa-Hui ChangChung-Lin LeeShuan-Pei LinChih-Kuang ChuangPublished in: International journal of molecular sciences (2019)
Hunter syndrome (mucopolysaccharidosis II; MPS II) is caused by a defect of the iduronate-2-sulfatase (IDS) gene. Few studies have reported integrated mutation data of Taiwanese MPS II phenotypes. In this study, we summarized genotype and phenotype correlations of confirmed MPS II patients and asymptomatic MPS II infants in Taiwan. Regular polymerase chain reaction and DNA sequencing were used to identify genetic abnormalities of 191 cases, including 51 unrelated patients with confirmed MPS II and 140 asymptomatic infants. IDS activity was analyzed in individual novel IDS variants using in vitro expression studies. Nineteen novel mutations were identified, in which the percentages of IDS activity of the novel missense mutations c.137A>C, c.311A>T, c.454A>C, c.797C>G, c.817C>T, c.998C>T, c.1106C>G, c.1400C>T, c.1402C>T, and c.1403G>A were significantly decreased (p < 0.001), c.254C>T and c.1025A>G were moderately decreased (p < 0.01), and c.851C>T was slightly decreased (p < 0.05) comparing with normal enzyme activity. The activities of the other six missense mutations were reduced but were insignificant. The results of genomic studies and their phenotypes were highly correlated. A greater understanding of the positive correlations may help to prevent the irreversible manifestations of Hunter syndrome, particularly in infants suspected of having asymptomatic MPS II. In addition, urinary glycosaminoglycan assay is important to diagnose Hunter syndrome since gene mutations are not definitive (could be non-pathogenic).
Keyphrases
- case report
- end stage renal disease
- newly diagnosed
- gene expression
- chronic kidney disease
- high throughput
- genome wide
- single cell
- dna methylation
- squamous cell carcinoma
- pulmonary embolism
- ejection fraction
- single molecule
- autism spectrum disorder
- patient reported outcomes
- electronic health record
- replacement therapy
- binding protein
- patient reported